**Author details**

Sultan Gulce-Iz1,2,3\* and Pelin Saglam-Metiner2

1 Department of Bioengineering, Faculty of Engineering, Ege University, Izmir, Turkey

2 Bioengineering Graduate Programme, Institute of Natural and Applied Sciences, Ege University, Izmir, Turkey

3 Biomedical Technologies Graduate Programme, Institute of Natural and Applied Sciences, Ege University, Izmir, Turkey

\*Address all correspondence to: sultangulce@gmail.com

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**143**

*Current State of the Art in DNA Vaccine Delivery and Molecular Adjuvants: Bcl-xL…*

2004

[8] Morse MA, CLAY TM, Lyerly HK. Handbook of Cancer Vaccines. Totowa, New Jersey: Humana Press;

[9] Hackett CJ, Harn DA, editors. Vaccine Adjuvants Immunological and Clinical Principles. Totowa, New Jersey:

[10] Saltzman WM, Shen H, Brandsma JL. DNA Vaccines: Methods and Protocols. 2nd ed. In: Hackworth J, editor. Totowa, New Jersey: Humana Press Inc; 2006. DOI: 10.1385/1597451681

[11] Singh M, editor. Vaccine Adjuvants and Delivery Systems. Emeryville, California, United States of America:

[12] Rajčáni J, Moško T, Režuchová I. Current developments in viral DNA vaccines: Shall they solve the unsolved? Reviews in Medical Virology. 2005. DOI:

[13] Smooker PM, Rainczuk A, Kennedy N, Spithill TW. DNA vaccines and their application against parasites—Promise, limitations and potential solutions. Biotechnology Annual Review. 2004. DOI: 10.1016/S1387-2656(04)10007-0

[14] Colluru VT, Johnson LE, Olson BM, McNeel DG. Preclinical and clinical development of DNA

vaccines for prostate cancer. Urologic Oncology: Seminars and Original Investigations. 2016. DOI: 10.1016/j.

innovations in mRNA vaccines. Current Opinion in Immunology. 2016. DOI:

[16] Oster CG, Kim N, Grode L, Barbu-Tudoran L, Schaper AK, Kaufmann SHE, et al. Cationic microparticles consisting of poly(lactide-co-glycolide)

[15] Ulmer JB, Geall AJ. Recent

10.1016/j.coi.2016.05.008

Humana Press; 2006

John Wiley; 2007

10.1002/rmv.467

urolonc.2013.09.014

*DOI: http://dx.doi.org/10.5772/intechopen.82203*

[1] Gregory AE, Titball R, Williamson D. Vaccine delivery using nanoparticles. Frontiers in Cellular and Infection Microbiology. 2013. DOI: 10.3389/

[2] Silveira MM, Oliveira TL, Schuch RA, McBride AJA, Dellagostin OA, Hartwig DD. DNA vaccines against leptospirosis: A literature review. Vaccine. 2017. DOI: 10.1016/j.

[3] Zahm CD, Colluru VT, McNeel DG. DNA vaccines for prostate cancer. Pharmacology & Therapeutics. 2017. DOI: 10.1016/j.pharmthera.2017.02.016

[4] Gülçe Iz S, Döşkaya M, Borrego B, Rodriguez F, Gürüz Y, Gürhan ID. Co-expression of the Bcl-xL antiapoptotic protein enhances the induction of Th1-like immune responses in mice immunized with DNA vaccines encoding FMDV B and T cell epitopes. Veterinary Research Communications. 2013. DOI: 10.1007/

[5] Gülçe Iz S, Döşkaya M, Caner A, Döşkaya AD, Rodriguez F, Gürüz Y, et al. A novel dual promoter DNA vaccine induces CD8+ response against toxoplasma gondii sporozoite specific surface protein "sporoSAG" through non-apoptotic cells. Trials in Vaccinology. 2014. DOI: 10.1016/j.

[6] Efe İris FN. Antijen ve Antijen Sunumu. Turkiye Klinikleri Journal of Infectious Diseases Special Topics.

[7] Tüting T, Austyn J, Storkus WJ, Falo LD. The immunology of DNA vaccines. In: Lowrie DB, Whalen RG, editors. DNA Vaccines: Methods and Protocols. Totowa, New Jersey: Humana

Press Inc; 2000. pp. 37-64. DOI:

10.1385/1592596886

**References**

fcimb.2013.00013

vaccine.2017.08.067

s11259-013-9560-3

trivac.2014.04.003

2008;**1**:14-18

*Current State of the Art in DNA Vaccine Delivery and Molecular Adjuvants: Bcl-xL… DOI: http://dx.doi.org/10.5772/intechopen.82203*
